

* NOTICES *

JPO and INPIT are not responsible for any damages caused by the use of this translation.

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.**** shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

CLAIMS

[Claim(s)]

[Claim 1]

Administration to a patient who needs a therapy of hepatitis C virus infection of a therapy top of TLR7 ligand or a salt permitted by the drugs, a hydrate, or a stereoisomeric form or a prevention top effective dose is included.

A therapeutic method of hepatitis C virus infection of a patient characterized by things.

[Claim 2]

It is a therapeutic method of hepatitis C virus infection of a patient including administration to a patient who needs a therapy of hepatitis C virus infection of a therapy top of TLR7 ligand or a salt permitted by the drugs, a hydrate, or a stereoisomeric form, or a prevention top effective dose, TLR7 ligand is chosen from an analog and a derivative of guanosine, imidazoquinoline, adenine, and pyrimidine.


A method characterized by things.

[Claim 3]

A salt or a hydrate permitted by drugs of TLR7 ligand or a salt permitted by the drugs, a hydrate, metabolite, a stereoisomeric form, or said stereoisomeric form is chosen from a following formula.

A method according to claim 2 characterized by things

[Formula 1]



Inside of a formula :

R^1 is the aryl group or heteroaryl group which is not replaced [the alkyl group which is not replaced / the substitution with which more than a kind of H or O, S, or N hetero atom may be inserted and crowded in between, or /, an alkenyl group, an alkynyl group, substitution, or], respectively.;

R^2 H, an OH radical, a sulfhydryl group, a halo group, Or an alkyl group which is not replaced [substitution or], an alkenyl group, or an alkynyl group with which more than a kind of O, S, or N hetero atom may be inserted and crowded in between, Or they are a -O-(alkyl) basis which is not replaced [substitution or], a -O-(aryl) basis, a -O-(heteroaryl) basis, a -S-(alkyl) basis, a -S-(aryl) basis, -S (heteroaryl) basis, an aryl group, or a heteroaryl group.;

R^3 H, an OH radical, a sulfhydryl group, Or an alkyl group which is not replaced [substitution or], an alkenyl group, an alkynyl group, An aryl group, a heteroaryl group, a -O-(alkyl) basis, a -O-(aryl) basis, -O-(heteroaryl) basis, a -S-(alkyl) basis, a -S-(aryl) basis, -S-(heteroaryl) basis, -NH (alkyl) group, -NH (aryl) group, - They are NH (heteroaryl) group, -NH (R^4) (alkyl) basis, -NH (R^4) (aryl) basis, or -NH (R^4) (heteroaryl) basis (the inside of a formula and R^4 are alkyl groups which are not replaced [substitution or]).;

X is O or S.;

Y is an alkyl group or an aryl group which is not replaced [H, a halo group, an OH radical, OR⁴ group, a sulfhydryl group, SR⁴ group, substitution, or];

Z is H, a halo group, an OH radical, OR⁴ group, a sulfhydryl group, or SR⁴ group.

[Claim 4]

TLR7 ligand -- the formula Ia, Ib, Ic, Id, Ie, If, Ig, and Ih (the inside of a formula, and R¹ -- H.) ;R² which is an alkyl group which is not replaced [substitution or], an alkenyl group, or an alkynyl group Or H, an OH radical, a halo group, Or an alkyl group which is not replaced [substitution or], an alkenyl group, or an alkynyl group, ;R³ which is a -CH₂-O-(alkyl) basis Or H, an OH radical, a sulfhydryl group, ;Y whose;X which is a -O-(alkyl) basis which is not replaced [substitution or], a -S-(alkyl) basis, or -NH (alkyl) group is O or S Or H, ; which is a halo group, an OH radical, OR⁴ group, a sulfhydryl group, or SR⁴ group, and Z are chosen from being H, a halo group, an OH radical, OR⁴ group, a sulfhydryl group, or SR⁴ group.


A method according to claim 2 characterized by things.

[Claim 5]

TLR7 ligand is chosen from a following formula.

A method according to claim 2 characterized by things.

[Formula 2]



[Claim 6]

A patient is human being.

A method according to claim 2 characterized by things.

[Claim 7]

Administration of a plastic remedy permitted by drugs, a carrier, or a medium is included further.

A method according to claim 2 characterized by things.

[Claim 8]

Administration of further therapeutic reagent is included further.

A method according to claim 2 characterized by things.

[Claim 9]

Further therapeutic reagent is an antiviral drug.

A method according to claim 8 characterized by things.

[Claim 10]

A therapy top or a prevention top effective dose is the day 0.001 - 100 mg/kg.

A method according to claim 2 characterized by things.

[Claim 11]

A therapy top or a prevention top effective dose is day about 0.01 to 50 mg/kg.

A method according to claim 10 characterized by things.

[Claim 12]

A therapy top or a prevention top effective dose is day about 0.1 to 20 mg/kg.

A method according to claim 11 characterized by things.

[Claim 13]

Parenteral administration of the TLR7 ligand is carried out.

A method according to claim 2 characterized by things.

[Claim 14]

TLR7 ligand is administered intravenously.

A method according to claim 2 characterized by things.

[Claim 15]